Trovagene Investor Relations http://trovagene.investorroom.com/ Trovagene Investor Relations Trovagene Strengthens Board of Directors with Appointment of Oncology Development Veteran Dr. Athena Countouriotis http://trovagene.investorroom.com/2017-09-20-Trovagene-Strengthens-Board-of-Directors-with-Appointment-of-Oncology-Development-Veteran-Dr-Athena-Countouriotis Dr. Athena Countouriotis joins Trovagene's Board of Directors, bringing significant experience in oncology clinical development and orphan indications Wed, 20 Sep 2017 05:00:00 -0700 http://trovagene.investorroom.com/2017-09-20-Trovagene-Strengthens-Board-of-Directors-with-Appointment-of-Oncology-Development-Veteran-Dr-Athena-Countouriotis Trovagene Announces Participation at the 19th Annual Rodman & Renshaw Global Investment Conference in New York City September 10-12, 2017 http://trovagene.investorroom.com/2017-08-31-Trovagene-Announces-Participation-at-the-19th-Annual-Rodman-Renshaw-Global-Investment-Conference-in-New-York-City-September-10-12-2017 Thu, 31 Aug 2017 05:00:00 -0700 http://trovagene.investorroom.com/2017-08-31-Trovagene-Announces-Participation-at-the-19th-Annual-Rodman-Renshaw-Global-Investment-Conference-in-New-York-City-September-10-12-2017 Trovagene's PLK1 Inhibitor PCM-075 Demonstrates Synergy with a HDAC Inhibitor in Non-Hodgkin Lymphoma Cell Lines http://trovagene.investorroom.com/2017-08-21-Trovagenes-PLK1-Inhibitor-PCM-075-Demonstrates-Synergy-with-a-HDAC-Inhibitor-in-Non-Hodgkin-Lymphoma-Cell-Lines Additionally, Trovagene announces PCM-075 synergy in combination with more than ten chemo and targeted therapeutics across a broad range of solid tumor and hematologic malignancies Mon, 21 Aug 2017 05:00:00 -0700 http://trovagene.investorroom.com/2017-08-21-Trovagenes-PLK1-Inhibitor-PCM-075-Demonstrates-Synergy-with-a-HDAC-Inhibitor-in-Non-Hodgkin-Lymphoma-Cell-Lines Trovagene's PLK1 Inhibitor PCM-075, in Preclinical AML Data, Significantly Enhances the Efficacy of a FLT3 inhibitor in Combination Therapy http://trovagene.investorroom.com/2017-08-16-Trovagenes-PLK1-Inhibitor-PCM-075-in-Preclinical-AML-Data-Significantly-Enhances-the-Efficacy-of-a-FLT3-inhibitor-in-Combination-Therapy Human AML xenograft with FLT3 mutation shows PCM-075 in combination with Quizartinib resulted in 96% tumor growth inhibition with tumor regression Wed, 16 Aug 2017 05:00:00 -0700 http://trovagene.investorroom.com/2017-08-16-Trovagenes-PLK1-Inhibitor-PCM-075-in-Preclinical-AML-Data-Significantly-Enhances-the-Efficacy-of-a-FLT3-inhibitor-in-Combination-Therapy Trovagene Announces Second Quarter 2017 Company Highlights and Financial Results http://trovagene.investorroom.com/2017-08-09-Trovagene-Announces-Second-Quarter-2017-Company-Highlights-and-Financial-Results Wed, 09 Aug 2017 13:26:00 -0700 http://trovagene.investorroom.com/2017-08-09-Trovagene-Announces-Second-Quarter-2017-Company-Highlights-and-Financial-Results